ZOM | Zomedica Corp. Stock Overview

(Stock Exchange: AMEX)

Day's Range	0.1196 - 0.1253
52 Week Range	0.1170 - 0.2290
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	6,541,816
Average Volume	5,145,266
Shares Outstanding	979,950,000
Market Cap	122,787,735
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2017-11-21

Valuation
Profitability
Growth
Health
P/E Ratio	-1.79
Forward P/E Ratio	-13.95
EPS	-0.07
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	144
Country	USA
Website	ZOM

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.

ZOM's peers: TLRY, ACB, CGC, HEXO, OGI, SHPH, MNK, AGRX, LFCR, AQST, LSDI, ALIM, ADMP, ATNX, CRON, SNDL

*Chart delayed

Analyzing fundamentals for ZOM we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ZOM Fundamentals page.

Watching at ZOM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZOM Technicals page.